SIETES :: 93213 citas

Resultados de la búsqueda por VALOR DUDOSO REFINAR BÚSQUEDA

1.

Godlee F. Covid-19: The lost lessons of Tamiflu. BMJ 2020;371:3 de diciembre. [Ref.ID 103804]

2.

Doshi P. Covid-19 vaccine trial protocols released. BMJ 2020:m4058. [Ref.ID 103766]

3.

Cohen J, Kupferschmidt K. The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug. Science Magazine 2020:1. [Ref.ID 103758]

4.

Samper E. Remdesivir: el culebrón de un fármaco sobrevalorado que parece acercarse a su fin. eldiario.es 2020:19 de octubre. [Ref.ID 103750]

5.

Ward BJ, Makarkov A, Séguin A, Pillet S, Trépanier S, Dhaliwall J, Libman MD, Vesikari T, Landry N. Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (=65 years): two multicentre, randomised phase 3 trials. Lancet 2020;396:13 de octubre. [Ref.ID 103743]

6.

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, et al for the ac, et al, et al. for the ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 — Final report. N Engl J Med 2020;383:8 de octubre. [Ref.ID 103731]

7.

Pau AK, Aberg J, Baker J, Belperio S, Crew P, Gidden DV, Grund B, Gulick RM, Harrison C, Kim A, Lane C, Masur H, Sheikh V, Singh K, Yazdany J, Tebas P, for the National Institutes of Health COVID-19 Treatment Guidelines. Convalescent plasma for the treatment of COVID-19: perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. Ann Intern Med 2020:25 de septiembre. [Ref.ID 103723]

8.

Qaseem A, McLean RM, O'Gurek D, Batur P, Lin K, Kansagara DL. Nonpharmacologic and pharmacologic management of acute pain from non–low back, musculoskeletal injuries in adults: A clinical guideline from the American College of Physicians and American Academy of Family Physicians. Ann Intern Med 2020;173:18 de agosto. [Ref.ID 103707]

9.

Rai V. What is the evidence for the use of potassium permanganate for wound care?. Drug Ther Bull 2020;58:mayo. [Ref.ID 103653]

10.

Anónimo. Domperidona*: supresión de la indicación en pediatría y recordatorio de las contraindicaciones en adultos y adolescentes. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2020;Referencia: MUH (FV), 3/2020:24 de febrero. [Ref.ID 103639]

11.

Mathieson S, Lin C-WC, Underwood M, Eldabe S. Pregabalin and gabapentin for pain. BMJ 2020;369:28 de abril. [Ref.ID 103627]

12.

PM Group. Gilead’s remdesivir appears to fail in leaked COVID-19 trial data. PMLiVE 2020:24 de abril. [Ref.ID 103590]

13.

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure F-X, Nicastri E, Oda R, et al.. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020;382:11 de junio. [Ref.ID 103581]

14.

Barnett ML. Opioid prescribing in the midst of crisis — Myths and realities. N Engl J Med 2020;382:19 de marzo. [Ref.ID 103579]

15.

Jefferson T, Jones M, Al Ansari LA, Bzaweer G, Beller E, Clark J, Conly J, Del Mar C, Dooley E, Ferroni E, Glasziou P, Hoffman T, Thorning S, van Driel M. Physical interventions to interrupt or reduce the spread of respiratory viruses. Part 1 - Face masks, eye protection and person distancing: systematic review and meta-analysis. medRxiv 2020:30 de marzo. [Ref.ID 103573]

16.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, et al.. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;382:7 de mayo. [Ref.ID 103564]

17.

Corbella J. Un fármaco antigripal, la nueva esperanza ante el coronavirus. La Vanguardia 2020:20 de marzo. [Ref.ID 103562]

18.

Mahase E. Esketamine for treatment resistant depression is not recommended by NICE. BMJ 2020;368:30 de enero. [Ref.ID 103542]

19.

Anónimo. Melatonin for jet lag. Drug Ther Bull 2020;58:enero. [Ref.ID 103526]

20.

Butler CC, van der Velden AW, Bongard E, Saville BR, Holmes J, Coenen S, Cook J, et al.. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet 2020;395:4 de enero. [Ref.ID 103501]